AgomAb Therapeutics NV (AGMB) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($447.2 million vs $364.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | TTRX |
|---|---|---|
| Share price | $9.08 | $12.00 |
| Market cap | $447.17M | $364.41M |
| 1-day change | -1.52% | +5.36% |
| YTD return | — | +204.57% |
| 1-year return | — | +30.43% |
| EPS (TTM) | $-2.08 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $16.45 |
| 52-week low | $7.97 | $2.57 |
| Distance from 52-week high | -49.05% | -27.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +314.87% | +108.33% |
| Average volume | 140.06K | 109.59K |
| Shares outstanding | 49.25M | 30.37M |
| Employees | 62 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
AGMB vs TTRX FAQ
Which is bigger, AgomAb Therapeutics NV or Turn Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $447.17M compared with $364.41M for Turn Therapeutics (TTRX).
Are AgomAb Therapeutics NV and Turn Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for Turn Therapeutics.